ArticleThe pharmacogenomics journal2010
Consistency of predictive signature genes and classifiers generated using different microarray platforms.
Article in The pharmacogenomics journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Consensus findings of an International Workshops on Genotoxicity Testing workshop on using transcriptomic biomarkers to predict genotoxicity.Environmental and molecular mutagenesis · 2025Review
- Progress in toxicogenomics to protect human health.Nature reviews. Genetics · 2025Review
- Protocol for using Ciclops to build models trained on cross-platform transcriptome data for clinical outcome prediction.STAR protocols · 2022Article
- Toxicogenomic module associations with pathogenesis: a network-based approach to understanding drug toxicity.The pharmacogenomics journal · 2018Article
- A Comparison of the TempO-Seq S1500+ Platform to RNA-Seq and Microarray Using Rat Liver Mode of Action Samples.Frontiers in genetics · 2018Article
- Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line.Nucleic acids research · 2016Article
- The FDA's Experience with Emerging Genomics Technologies-Past, Present, and Future.The AAPS journal · 2016Review
- Competence Classification of Cumulus and Granulosa Cell Transcriptome in Embryos Matched by Morphology and Female Age.PloS one · 2016Article
- An investigation of biomarkers derived from legacy microarray data for their utility in the RNA-seq era.Genome biology · 2014Article
- The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance.Nature biotechnology · 2014Article
- Microarray-based RNA profiling of breast cancer: batch effect removal improves cross-platform consistency.BioMed research international · 2014Article
- Prediction of clinically relevant safety signals of nephrotoxicity through plasma metabolite profiling.BioMed research international · 2013Article
- A network pharmacology approach to evaluating the efficacy of chinese medicine using genome-wide transcriptional expression data.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Evaluation of drug-induced tissue injury by measuring alanine aminotransferase (ALT) activity in silkworm hemolymph.BMC pharmacology & toxicology · 2012Article
- Direct integration of intensity-level data from Affymetrix and Illumina microarrays improves statistical power for robust reanalysis.BMC medical genomics · 2012Article
- Reverse engineering biomolecular systems using -omic data: challenges, progress and opportunities.Briefings in bioinformatics · 2012Article
- Quality assurance of RNA expression profiling in clinical laboratories.The Journal of molecular diagnostics : JMD · 2012Review
- Microarrays, deep sequencing and the true measure of the transcriptome.BMC biology · 2011Review
- Article
- Clinical implementation of RNA signatures for pharmacogenomic decision-making.Pharmacogenomics and personalized medicine · 2011Article
Corrections and comments
- Commented on by
Authors and funding
24 authors.
Funding
Abstract
Microarray-based classifiers and associated signature genes generated from various platforms are abundantly reported in the literature; however, the utility of the classifiers and signature genes in cross-platform prediction applications remains largely uncertain. As part of the MicroArray Quality Control Phase II (MAQC-II) project, we show in this study 80-90% cross-platform prediction consistency using a large toxicogenomics data set by illustrating that: (1) the signature genes of a classifier generated from one platform can be directly applied to another platform to develop a predictive classifier; (2) a classifier developed using data generated from one platform can accurately predict samples that were profiled using a different platform. The results suggest the potential utility of using published signature genes in cross-platform applications and the possible adoption of the published classifiers for a variety of applications. The study reveals an opportunity for possible translation of biomarkers identified using microarrays to clinically validated non-array gene expression assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.